Stoke Therapeutics Inc (STOK) is now in the Overvalued zone, suggesting that its current forward PS ratio of 99.55 is considered Overvalued compared with the five-year average of -7.01. The fair price of Stoke Therapeutics Inc (STOK) is between 12.25 to 26.90 according to relative valuation method. Compared to the current price of 33.78 USD , Stoke Therapeutics Inc By Overvalued By 25.59%.

Relative Value

Fair Zone

12.25-26.90

Current Price：33.78

25.59%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Stoke Therapeutics Inc (STOK) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Stoke Therapeutics Inc (STOK) has a current Price-to-Book (P/B) ratio of 5.53. Compared to its 3-year average P/B ratio of 2.62, the current P/B ratio is approximately 111.26% higher. Relative to its 5-year average P/B ratio of 2.91, the current P/B ratio is about 90.12% higher. Stoke Therapeutics Inc (STOK) has a Forward Free Cash Flow (FCF) yield of approximately 2.97%. Compared to its 3-year average FCF yield of -15.54%, the current FCF yield is approximately -119.10% lower. Relative to its 5-year average FCF yield of -11.54%, the current FCF yield is about -125.70% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for STOK competitors is 109.09, providing a benchmark for relative valuation. Stoke Therapeutics Inc Corp (STOK.O) exhibits a P/S ratio of 99.55, which is -8.75% above the industry average. Given its robust revenue growth of 117.25%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of STOK increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of STOK in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is STOK currently overvalued or undervalued?

What is Stoke Therapeutics Inc (STOK) fair value?

STOK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Stoke Therapeutics Inc (STOK) is between 12.25 to 26.90 according to relative valuation method.

How does STOK's valuation metrics compare to the industry average?

The average P/S ratio for STOK's competitors is 109.09, providing a benchmark for relative valuation. Stoke Therapeutics Inc Corp (STOK) exhibits a P/S ratio of 99.55, which is -8.75% above the industry average. Given its robust revenue growth of 117.25%, this premium appears sustainable.

What is the current P/B ratio for Stoke Therapeutics Inc (STOK) as of Mar 03 2026?

As of Mar 03 2026, Stoke Therapeutics Inc (STOK) has a P/B ratio of 5.53. This indicates that the market values STOK at 5.53 times its book value.

What is the current FCF Yield for Stoke Therapeutics Inc (STOK) as of Mar 03 2026?

As of Mar 03 2026, Stoke Therapeutics Inc (STOK) has a FCF Yield of 2.97%. This means that for every dollar of Stoke Therapeutics Inc's market capitalization, the company generates 2.97 cents in free cash flow.

What is the current Forward P/E ratio for Stoke Therapeutics Inc (STOK) as of Mar 03 2026?

As of Mar 03 2026, Stoke Therapeutics Inc (STOK) has a Forward P/E ratio of -9.98. This means the market is willing to pay $-9.98 for every dollar of Stoke Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Stoke Therapeutics Inc (STOK) as of Mar 03 2026?

As of Mar 03 2026, Stoke Therapeutics Inc (STOK) has a Forward P/S ratio of 99.55. This means the market is valuing STOK at $99.55 for every dollar of expected revenue over the next 12 months.

STOK Valuation